Amneal Pharmaceuticals Stock Cash Flow From Operations
| 2DT Stock | EUR 7.30 0.25 3.31% |
Amneal Pharmaceuticals fundamentals help investors to digest information that contributes to Amneal Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Amneal Stock. The fundamental analysis module provides a way to measure Amneal Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Amneal Pharmaceuticals stock.
Amneal |
Amneal Pharmaceuticals Company Cash Flow From Operations Analysis
Amneal Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Amneal Pharmaceuticals Cash Flow From Operations | 241.82 M |
Most of Amneal Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Amneal Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Amneal Pharmaceuticals has 241.82 M in Cash Flow From Operations. This is 54.14% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash flow from operations for all Germany stocks is 75.1% higher than that of the company.
Amneal Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Amneal Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Amneal Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Amneal Pharmaceuticals by comparing valuation metrics of similar companies.Amneal Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Amneal Fundamentals
| Return On Equity | -0.88 | |||
| Return On Asset | 0.0257 | |||
| Profit Margin | (0.06) % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 2.95 B | |||
| Shares Outstanding | 151.48 M | |||
| Shares Owned By Insiders | 10.80 % | |||
| Shares Owned By Institutions | 67.79 % | |||
| Price To Earning | 8.70 X | |||
| Price To Book | 1.17 X | |||
| Price To Sales | 0.29 X | |||
| Revenue | 2.09 B | |||
| Gross Profit | 783.95 M | |||
| EBITDA | 401.1 M | |||
| Net Income | 10.62 M | |||
| Cash And Equivalents | 452.1 M | |||
| Cash Per Share | 3.04 X | |||
| Total Debt | 2.72 B | |||
| Debt To Equity | 7.78 % | |||
| Current Ratio | 2.45 X | |||
| Book Value Per Share | 1.96 X | |||
| Cash Flow From Operations | 241.82 M | |||
| Earnings Per Share | (0.73) X | |||
| Target Price | 7.33 | |||
| Number Of Employees | 7 K | |||
| Beta | 1.37 | |||
| Market Capitalization | 712.21 M | |||
| Total Asset | 3.94 B | |||
| Net Asset | 3.94 B |
About Amneal Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amneal Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amneal Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amneal Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Amneal Stock
Amneal Pharmaceuticals financial ratios help investors to determine whether Amneal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amneal with respect to the benefits of owning Amneal Pharmaceuticals security.